Approach
A point-of-care system for preparing an autologous whole blood clot dressing.
← All products
Inspect image Illustrative photograph · Manufacturer reference ↗
RedDress
ActiGraft
An autologous approach using a clot prepared from the patient’s own blood.
Inspect image - Material / technology
- Patient-derived whole blood clot
- Format
- Point-of-care system
- Product source
- RedDress
THE PRODUCT IN CONTEXT
A closer look.
Understand the material, explore the source information, and bring the right questions to your clinical review.
Confirm the system
ActiGraft systems and versions have different instructions and components. Confirm the exact system supplied before training or use.
Read the evidence
Review the available clinical trials, populations, endpoints, and limitations in the evidence library.
CLINICAL READING
Follow the source.
Read the full reference to understand the population, application, and limits of the findings.
Explore the evidence library →Meta-analysis · 2026Snyder RJ, Lee M. Efficacy of autologous blood-derived therapies in diabetic foot ulcers: a systematic review and meta-analysis of randomized controlled trials. Wounds. 2026;38(7):184-190.RCT · 2024Snyder R, Nouvong A, Ulloa J, et al. Efficacy and safety of autologous whole blood clot in diabetic foot ulcers: a randomised controlled trial. J Wound Care. 2024;33(9):688-700.Prospective comparative · 2024Ram E, Zager Y, Carter D, et al. Efficacy and safety of RD2 Ver.02, a whole blood clot therapy, coupled with a minimally invasive procedure in pilonidal sinus: a phase II study. Tech Coloproctol. 2024;28(1):97.
YOUR NEXT STEP
Bring it into your practice’s conversation.
Ask for current instructions, available sizes, product training, and help reviewing operational requirements.